1. Home
  2. CMDB vs PROK Comparison

CMDB vs PROK Comparison

Compare CMDB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CMDB

Costamare Bulkers Holdings Limited

HOLD

Current Price

$17.47

Market Cap

403.4M

Sector

N/A

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$1.83

Market Cap

359.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMDB
PROK
Founded
2023
2015
Country
Monaco
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
403.4M
359.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CMDB
PROK
Price
$17.47
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.40
AVG Volume (30 Days)
41.9K
876.0K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1075.00
52 Week Low
$8.46
$0.54
52 Week High
$19.93
$7.13

Technical Indicators

Market Signals
Indicator
CMDB
PROK
Relative Strength Index (RSI) 53.32 55.41
Support Level $16.18 $1.73
Resistance Level $17.71 $1.96
Average True Range (ATR) 0.80 0.12
MACD 0.09 0.01
Stochastic Oscillator 63.28 74.60

Price Performance

Historical Comparison
CMDB
PROK

About CMDB Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing transportation of dry bulk commodities globally for a broad range of customers. Its vessels transport a broad range of bulks, such as iron ore, coal and grains and minor bulks, such as bauxite, phosphate fertilizers and steel products, across shipping routes globally. The company's vessel fleet includes Current Dry Bulk Fleet, Chartered-In Vessels Fleet, and Chartered-In Newbuilding Vessels. It operates under one reportable segment, that of operating dry bulk vessels.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: